Tropisetron is an approved anti-sickness medicine, sold as Navoban and related brands for preventing and treating the nausea and vomiting caused by chemotherapy.
Amounts reported for Tropisetron are listed under Reported protocols, each with its source and study kind. No amount ladder is inferred from them. This is educational source context, not a protocol or recommendation.
Enter a target amount only from your own reviewed source. The calculator can convert it into concentration, volume and device markings, but it will not infer an amount from product availability or another compound.
Only mcg or mg amounts are retained. The calculator derives mL, syringe units or pen clicks from the current vial strength, water volume and device.
Human study rows are described per source under Reported protocols; they belong to their trial populations and are not a general amount.
Verify the exact compound, formulation and amount against the product label or certificate before calculation.
Follow the product label, certificate and validated laboratory SOP; no universal storage assumption is applied here.
Label concentration and preparation date, use sterile technique where applicable, and follow a validated stability protocol.
What published studies and recent community write-ups report about amounts, timing and course length. 6 clinical, 1 preclinical and 1 community-reported rows, each linked to its source. These are descriptions of what others report, not instructions, and nothing here is medical advice.
| Context | Dose | Frequency | Route | Course | Source |
|---|---|---|---|---|---|
| Clinical6 rows | |||||
| Approved regulator label for chemotherapy-induced nauseaAdults from 15 years of age receiving moderately to highly emetogenic cytotoxic chemotherapy | One 5 mg capsule per day (5.64 mg of tropisetron hydrochloride) | Once daily | Oral capsule | 2 to 3 days on average, up to a maximum of 5 daysThe label sets a maximum of 5 consecutive days of treatment | Agence nationale de securite du medicament (ANSM), France2013 |
| This is the French medicines agency summary of product characteristics for Navoban 5 mg. It records headache and constipation as very common and drowsiness, abdominal pain, diarrhoea and fatigue as common, says use in children cannot be recommended for lack of experience, and warns that daily doses above 10 mg should be avoided in patients with uncontrolled high blood pressure. Tropisetron is not marketed in the United States and has no DailyMed label. | |||||
| Randomised placebo-controlled trial in schizophrenia40 patients with chronic schizophrenia stabilised on risperidone at 2 to 6 mg a day; 33 completed | 10 mg per day | Daily | Oral, added to existing risperidone | 8 weeksNone described | Annals of General Psychiatry (PubMed Central)2010 |
| Auditory sensory gating improved significantly in non-smoking patients and sustained visual attention improved on a standard cognitive battery, while the overall psychosis rating scale did not change. Quality-of-life scores improved across the whole group but not in the non-smoking subgroup alone. Forty patients is small, and smoking status mattered enough to split the result. | |||||
| Short-term dose comparison in schizophrenia40 non-smoking patients with schizophrenia on 3 to 6 mg a day of risperidone, with poor sensory gating at baseline | 5 mg, 10 mg or 20 mg per day, against placebo | Once daily | Oral, added to existing risperidone | 10 daysNone described | American Journal of Psychiatry (PubMed)2012 |
| All three doses improved overall cognitive scores after ten days, with 10 mg best for immediate memory and 20 mg best for delayed memory, and the cognitive gains tracked the normalisation of sensory gating. Two patients in the 20 mg group withdrew because of adverse effects while the lower doses were well tolerated. A separate study by the same group found measurable gains after a single day of dosing. | |||||
| Dose-finding trial in fibromyalgia418 patients with primary fibromyalgia | 5 mg, 10 mg or 15 mg per day, against placebo | Once daily | Oral | 10 daysNone described | International Journal of Clinical Pharmacology Research (PubMed)2001 |
| Only the 5 mg dose produced a significantly higher response rate than placebo, at 39.2 percent against 26.2 percent, along with less pain, fewer painful tender points and better sleep. The authors describe a bell-shaped dose-response curve, meaning more drug did not mean more effect, which is an unusual and important finding for anyone reading higher numbers elsewhere. Gastrointestinal symptoms were the most common adverse events. | |||||
| Longer open-label course in fibromyalgia30 women with fibromyalgia | 5 mg per day | Once daily | Oral | 28 daysNone described | Scandinavian Journal of Rheumatology Supplement (PubMed)2000 |
| Pain on a visual analogue scale fell by a mean 59.7 percent by day 28, with most of the change arriving by day 10 and a further drop after that, and anxiety and depression scores also improved. This arm was open-label with no control group, so expectation effects cannot be separated out, and it was run by staff at the manufacturer. | |||||
| Systematic review of sensory gating across 5-HT3 antagonists11 eligible human studies, eight in patients with schizophrenia stable on antipsychotics | Reviews the 5 to 20 mg daily range used in the tropisetron trials | Not stated | Oral | Not stated | Neuropsychopharmacology (PubMed Central)2022 |
| Five studies consistently found that 5-HT3 antagonists improved sensory gating in schizophrenia, and the review singles out tropisetron, with its added alpha7 nicotinic partial agonism, as also improving sustained visual attention in non-smoking patients. Evidence for other measures of sensory processing was inconsistent, and the authors flag small samples and the confounding effect of concurrent antipsychotics. | |||||
| Preclinical1 row | |||||
| Recognition memory in rats on long-term antipsychoticsRats treated orally with risperidone at 2.5 mg/kg per day or quetiapine at 25 mg/kg per day for 30 or 90 days | 3.0 mg/kg as a single injection | One acute dose before training | Injection, on top of chronic oral antipsychotic treatment | Single dose after 30 or 90 days of antipsychotic treatmentNot applicable | Biochemical Pharmacology (PubMed Central)2018 |
| Neither antipsychotic improved novel object recognition after a 48-hour delay, but a single dose of tropisetron markedly did, in animals that had been on either drug for a month or three months. The design deliberately tested the pro-cognitive compound against a realistic medication background. These are rat amounts and routes and do not convert to a human dose. | |||||
| Community-reported1 row | |||||
| Vendor capsule product | 5 mg per capsule, 60 capsules per bottle (300 mg total) | Not stated | Oral capsule | Not stated | Community resource2026 |
| A vendor claim about what ships, not a protocol. The 5 mg strength matches both the approved anti-sickness capsule and the dose that worked in fibromyalgia, but this is research-grade material rather than a licensed medicine, and the listing states it is not for human use. The product URL is also misspelled on the vendor's site. | |||||
Plus 2 community resources (dosing guides, forum threads and vendor write-ups), reported above but not linked.
Tropisetron is an approved anti-sickness medicine, sold as Navoban and related brands for preventing and treating the nausea and vomiting caused by chemotherapy, and it is the only compound in this part of the library with a regulator-approved product label. What put it into brain research is a second action: alongside blocking the 5-HT3 serotonin receptor it is a partial agonist at the alpha7 nicotinic acetylcholine receptor, the target most often linked to the sensory-gating and attention deficits of schizophrenia. Randomised trials have added 5 to 20 mg a day to antipsychotic treatment and reported improved cognition, sensory gating and negative symptoms, and earlier trials in several hundred fibromyalgia patients found a benefit at 5 mg that did not grow with higher doses.
These themes describe recurring questions in published research. They are not claims of effectiveness or recommendations for use.
Neuroplasticity, cognition, stress and sleep models.
This is the French medicines agency summary of product characteristics for Navoban 5 mg. It records headache and constipation as very common and drowsiness, abdominal pain, diarrhoea and fatigue as common, says use in.
Auditory sensory gating improved significantly in non-smoking patients and sustained visual attention improved on a standard cognitive battery, while the overall psychosis rating scale did not change. Quality-of-life.
All three doses improved overall cognitive scores after ten days, with 10 mg best for immediate memory and 20 mg best for delayed memory, and the cognitive gains tracked the normalisation of sensory gating. Two.
Only the 5 mg dose produced a significantly higher response rate than placebo, at 39.2 percent against 26.2 percent, along with less pain, fewer painful tender points and better sleep. The authors describe a.
Pain on a visual analogue scale fell by a mean 59.7 percent by day 28, with most of the change arriving by day 10 and a further drop after that, and anxiety and depression scores also improved. This arm was open-label.
Study models remain visible so laboratory and animal findings are not mistaken for established human outcomes.
6 protocol rows on this page come from human trials, trial registrations, regulator labels or reviews of human data. Approval status and populations are stated per row.
1 protocol row describe animal, cell or toxicology work. Amounts from these rows do not translate to people.
1 row record what blogs, vendor write-ups or forums describe for Tropisetron. None has been verified against primary literature.
Sequence, synonyms and registry identifiers as recorded in PubChem, the National Library of Medicine's open chemistry database. Formula, mass and CAS number are summarized at the top of the page.
Navoban, Novaban, ICS 205-930, Tropisetronum, UNII 6I819NIK1W, CHEMBL56564, ATC A04AA03
ZNRGQMMCGHDTEI-FUNVUKJBSA-N
[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 1H-indole-3-carboxylate
8 curated references, each with its journal, year and study model, plus 2 community resources reported but not linked.